SAKARNSESAKAR HEALTHCARE LIMITEDLowNeutral
Announced Fri, 24 Jul · 20:14 IST

Sakar Healthcare Q1 FY27 Results: Revenue up 38 percent, PAT up 120 percent YoY

SAKAR · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close
1-day move
₹804.45
prior close
₹817.45
base price
After-mkt
timing
5m10m15m30m1D2D3D4D5D7D15D1M2M3M
-2.2-1.3+0.0+0.8
Up moveDown movePending
AI summary

Sakar Healthcare reported Q1 FY27 consolidated revenue of Rs 7,297 lakhs, up 38 percent year on year. EBITDA rose 67 percent to Rs 2,125 lakhs with margin at 29 percent. Profit after tax surged 120 percent to Rs 1,028 lakhs, margin 14 percent. Growth was driven by new oncology market authorizations, strong export demand, and regulatory progress including 261 dossiers shared globally and 16 approvals. Tech transfer projects with partners like Accord-Intas, Torrent, Emcure, Glenmark, and Zydus are advancing.

Likely market impact

Strong quarter with doubled profits signals robust oncology growth and improving operating leverage, likely positive for investor sentiment.